Divi's Laboratories Ltd
DIVISLAB
Company Profile
Business description
Divi's Laboratories Ltd is engaged in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceutical Ingredients, with predominance in exports. Through its custom synthesis business, the Company supports innovator pharma companies for patented products from gram-scale requirements for clinical trials to launch and late-life cycle management, in addition to generics. It operates in a single operating segment, Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceutical Ingredients. The Company derives maximum revenue from Europe.
Contact
Cyber Hills
Divi Towers, 1-72/23(P)/DIVIS/303
Gachibowli
HyderabadTG500032
INDT: +91 4066966300
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
9,634
Stocks News & Analysis
stocks
Meta earnings: Early look at Muse adoption impresses investors
We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.
stocks
Tesla earnings: Shares fall on slower deliveries growth outlook; Raising valuation
Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,905.80 | 11.30 | -0.13% |
| CAC 40 | 7,782.82 | 28.44 | -0.36% |
| DAX 40 | 25,181.65 | 190.10 | -0.75% |
| Dow JONES (US) | 52,215.16 | 652.82 | -1.23% |
| FTSE 100 | 10,690.36 | 34.67 | -0.32% |
| HKSE | 23,093.37 | 158.69 | 0.69% |
| NASDAQ | 25,955.34 | 53.52 | -0.21% |
| Nikkei 225 | 62,693.16 | 214.68 | -0.34% |
| NZX 50 Index | 13,733.93 | 12.91 | -0.09% |
| S&P 500 | 7,623.68 | 39.75 | -0.52% |
| S&P/ASX 200 | 8,795.20 | 2.00 | 0.02% |
| SSE Composite Index | 3,690.48 | 32.45 | 0.89% |